244 related articles for article (PubMed ID: 35373517)
1. Inhibition of epidermal growth factor receptor suppresses parathyroid hormone-related protein expression in tumours and ameliorates cancer-associated cachexia.
Weber BZC; Agca S; Domaniku A; Bilgic SN; Arabaci DH; Kir S
J Cachexia Sarcopenia Muscle; 2022 Jun; 13(3):1582-1594. PubMed ID: 35373517
[TBL] [Abstract][Full Text] [Related]
2.
Fang XQ; Kim YS; Lee YM; Lee M; Lim WJ; Yim WJ; Han MW; Lim JH
Nutrients; 2022 Apr; 14(7):. PubMed ID: 35406121
[TBL] [Abstract][Full Text] [Related]
3. Parathyroid hormone-related protein serves as a prognostic indicator in oral squamous cell carcinoma.
Lv Z; Wu X; Cao W; Shen Z; Wang L; Xie F; Zhang J; Ji T; Yan M; Chen W
J Exp Clin Cancer Res; 2014 Dec; 33(1):100. PubMed ID: 25539663
[TBL] [Abstract][Full Text] [Related]
4. Reconstitution of amphiregulin-epidermal growth factor receptor signaling in lung squamous cell carcinomas activates PTHrP gene expression and contributes to cancer-mediated diseases of the bone.
Gilmore JL; Gonterman RM; Menon K; Lorch G; Riese DJ; Robling A; Foley J
Mol Cancer Res; 2009 Oct; 7(10):1714-28. PubMed ID: 19825997
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of epidermal growth factor receptor signalling reduces hypercalcaemia induced by human lung squamous-cell carcinoma in athymic mice.
Lorch G; Gilmore JL; Koltz PF; Gonterman RM; Laughner R; Lewis DA; Konger RL; Nadella KS; Toribio RE; Rosol TJ; Foley J
Br J Cancer; 2007 Jul; 97(2):183-93. PubMed ID: 17533397
[TBL] [Abstract][Full Text] [Related]
6. Extracellular vesicles-released parathyroid hormone-related protein from Lewis lung carcinoma induces lipolysis and adipose tissue browning in cancer cachexia.
Hu W; Xiong H; Ru Z; Zhao Y; Zhou Y; Xie K; Xiao W; Xiong Z; Wang C; Yuan C; Shi J; Du Q; Zhang X; Yang H
Cell Death Dis; 2021 Jan; 12(1):134. PubMed ID: 33510128
[TBL] [Abstract][Full Text] [Related]
7. Rare mutations of epidermal growth factor receptor in epidermal growth factor receptor-tyrosine kinase inhibitor-naive non-small cell lung carcinoma and the response to erlotinib therapy.
Sari M; Aydiner A
J Cancer Res Ther; 2020; 16(1):132-138. PubMed ID: 32362623
[TBL] [Abstract][Full Text] [Related]
8. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
Greenhalgh J; Boland A; Bates V; Vecchio F; Dundar Y; Chaplin M; Green JA
Cochrane Database Syst Rev; 2021 Mar; 3(3):CD010383. PubMed ID: 33734432
[TBL] [Abstract][Full Text] [Related]
9. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
[No Abstract] [Full Text] [Related]
10. Gastrin induces parathyroid hormone-like hormone expression in gastric parietal cells.
Al Menhali A; Keeley TM; Demitrack ES; Samuelson LC
Am J Physiol Gastrointest Liver Physiol; 2017 Jun; 312(6):G649-G657. PubMed ID: 28408643
[TBL] [Abstract][Full Text] [Related]
11. EZH2 inhibitors reverse resistance to gefitinib in primary EGFR wild-type lung cancer cells.
Gong H; Li Y; Yuan Y; Li W; Zhang H; Zhang Z; Shi R; Liu M; Liu C; Chen C; Liu H; Chen J
BMC Cancer; 2020 Dec; 20(1):1189. PubMed ID: 33276757
[TBL] [Abstract][Full Text] [Related]
12. Tyr1068-phosphorylated epidermal growth factor receptor (EGFR) predicts cancer stem cell targeting by erlotinib in preclinical models of wild-type EGFR lung cancer.
Sette G; Salvati V; Mottolese M; Visca P; Gallo E; Fecchi K; Pilozzi E; Duranti E; Policicchio E; Tartaglia M; Milella M; De Maria R; Eramo A
Cell Death Dis; 2015 Aug; 6(8):e1850. PubMed ID: 26247735
[TBL] [Abstract][Full Text] [Related]
13. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
Greenhalgh J; Dwan K; Boland A; Bates V; Vecchio F; Dundar Y; Jain P; Green JA
Cochrane Database Syst Rev; 2016 May; (5):CD010383. PubMed ID: 27223332
[TBL] [Abstract][Full Text] [Related]
14. Regulation of epidermal growth factor receptor tyrosine kinase inhibitor resistance via Ambra1-mediated autophagy in non-small cell lung cancer.
Chen YH; Yang Y; Xu LJ; Deng Y; Fu JW
J Physiol Pharmacol; 2023 Jun; 74(3):. PubMed ID: 37661184
[TBL] [Abstract][Full Text] [Related]
15. Tumour-derived PTH-related protein triggers adipose tissue browning and cancer cachexia.
Kir S; White JP; Kleiner S; Kazak L; Cohen P; Baracos VE; Spiegelman BM
Nature; 2014 Sep; 513(7516):100-4. PubMed ID: 25043053
[TBL] [Abstract][Full Text] [Related]
16. Effects of S-pindolol in mouse pancreatic and lung cancer cachexia models.
Springer J; Jové Q; de Lima Junior EA; Ladrón NÁ; López-Soriano FJ; Busquets S; Argiles JM; Marks DL
J Cachexia Sarcopenia Muscle; 2023 Jun; 14(3):1244-1248. PubMed ID: 37130578
[TBL] [Abstract][Full Text] [Related]
17. Streptonigrin Mitigates Lung Cancer-induced Cachexia by Suppressing TCF4/TWIST1-induced PTHLH Expression.
Fang XQ; Lee S; Kim YS; Han GE; Lim CH; Lim JH
Anticancer Res; 2023 Mar; 43(3):1149-1157. PubMed ID: 36854496
[TBL] [Abstract][Full Text] [Related]
18. Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: the effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab.
Chen G; Kronenberger P; Teugels E; Umelo IA; De Grève J
BMC Med; 2012 Mar; 10():28. PubMed ID: 22436374
[TBL] [Abstract][Full Text] [Related]
19. Mediating EGFR-TKI Resistance by VEGF/VEGFR Autocrine Pathway in Non-Small Cell Lung Cancer.
Osude C; Lin L; Patel M; Eckburg A; Berei J; Kuckovic A; Dube N; Rastogi A; Gautam S; Smith TJ; Sreenivassappa SB; Puri N
Cells; 2022 May; 11(10):. PubMed ID: 35626731
[TBL] [Abstract][Full Text] [Related]
20. Cetuximab Inhibits T790M-Mediated Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in a Lung Adenocarcinoma Patient-Derived Xenograft Mouse Model.
Martin P; Stewart E; Pham NA; Mascaux C; Panchal D; Li M; Kim L; Sakashita S; Wang D; Sykes J; Friess T; Shepherd FA; Liu G; Tsao MS
Clin Lung Cancer; 2016 Sep; 17(5):375-383.e2. PubMed ID: 26926157
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
